Latikafusp represents a distinct treatment method for treating particular cancers, particularly cases involving aberrant ALK proteins. This agent functions as an blocker of altered ALK structures, demonstrating efficacy in research trials and phase human studies. Its mechanism of action offers a precise method to block cancer development and potent